• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微 RNA 调控皮肤 T 细胞淋巴瘤中 T 细胞耗竭。

MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma.

机构信息

Division of Dermatology, Department of Surgery, City of Hope National Medical Center, Duarte, California, USA; Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.

Irell and Manella Graduate School of Biological Sciences, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.

出版信息

J Invest Dermatol. 2022 Mar;142(3 Pt A):603-612.e7. doi: 10.1016/j.jid.2021.08.447. Epub 2021 Nov 11.

DOI:10.1016/j.jid.2021.08.447
PMID:34774537
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8860868/
Abstract

Cutaneous T cell lymphoma (CTCL) is characterized by a background of chronic inflammation, where malignant CTCL cells escape immune surveillance. To study how microRNAs (miRs) regulate T-cell exhaustion, we performed miR sequencing analysis, qRT-PCR, and in situ hybridization on 45 primary CTCL samples, three healthy skin samples, and CTCL cell lines, identifying miR-155-5p, miR-130b-3p, and miR-21-3p. Moreover, miR-155-5p, miR-130b-3p, and miR-21-3p positively correlated with immune checkpoint gene expression in lesional skin samples and were enriched in the IL-6/Jak/signal transducer and activator of transcription signaling pathway by gene set enrichment analysis. Further gene sequencing analysis showed decreased mRNA expression of the major negative regulators of Jak/signal transducer and activator of transcription signaling: SOCS, PIAS, and PTPN. Transfection of MyLa and HuT78 cells with anti-miR-155-5p, anti‒miR-21-3p, and anti‒miR-130b revealed a considerable increase in SOCS proteins along with a significant decrease in the levels of activated signal transducer and activator of transcription 3 and immune checkpoint surface protein expression as well as decreased cell proliferation. Downregulation of miR-155, miR-130, and miR-21 in CTCL cell lines decreased CTCL cell growth and facilitated CD8 T-cell-mediated cytotoxic activity, with concordant production of IFN-γ and CD107a expression. Our results describe the mechanisms of miR-induced T-cell exhaustion, which provide a foundation for developing synthetic anti-miRs to therapeutically target the tumor microenvironment in CTCL.

摘要

皮肤 T 细胞淋巴瘤 (CTCL) 的特征是慢性炎症背景,其中恶性 CTCL 细胞逃避免疫监视。为了研究 microRNAs (miRs) 如何调节 T 细胞衰竭,我们对 45 个原发性 CTCL 样本、3 个健康皮肤样本和 CTCL 细胞系进行了 miR 测序分析、qRT-PCR 和原位杂交,鉴定出 miR-155-5p、miR-130b-3p 和 miR-21-3p。此外,miR-155-5p、miR-130b-3p 和 miR-21-3p 在病变皮肤样本中与免疫检查点基因表达呈正相关,并且通过基因集富集分析在 IL-6/Jak/信号转导和转录激活因子信号通路中富集。进一步的基因测序分析显示 Jak/信号转导和转录激活因子主要负调节剂的 mRNA 表达减少:SOCS、PIAS 和 PTPN。用抗 miR-155-5p、抗 miR-21-3p 和抗 miR-130b 转染 MyLa 和 HuT78 细胞,发现 SOCS 蛋白表达显著增加,同时激活的信号转导和转录激活因子 3 和免疫检查点表面蛋白表达水平显著降低,细胞增殖减少。CTCL 细胞系中 miR-155、miR-130 和 miR-21 的下调降低了 CTCL 细胞的生长,并促进了 CD8 T 细胞介导的细胞毒性活性,同时伴有 IFN-γ 和 CD107a 表达的协同产生。我们的结果描述了 miR 诱导的 T 细胞衰竭的机制,为开发合成抗 miR 来治疗性靶向 CTCL 肿瘤微环境提供了基础。

相似文献

1
MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma.微 RNA 调控皮肤 T 细胞淋巴瘤中 T 细胞耗竭。
J Invest Dermatol. 2022 Mar;142(3 Pt A):603-612.e7. doi: 10.1016/j.jid.2021.08.447. Epub 2021 Nov 11.
2
MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.蕈样肉芽肿早期的 microRNA 表达与特应性皮炎和晚期皮肤 T 细胞淋巴瘤明显不同。
Anticancer Res. 2014 Dec;34(12):7207-17.
3
Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.组蛋白去乙酰化酶抑制剂通过恢复晚期皮肤T细胞淋巴瘤中一种肿瘤抑制性微小RNA-150来抑制转移。
Oncotarget. 2017 Jan 31;8(5):7572-7585. doi: 10.18632/oncotarget.13810.
4
Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.皮肤T细胞淋巴瘤(CTCL)患者及患者来源细胞系中STAT4表达的分析。
Cell Cycle. 2014;13(18):2975-82. doi: 10.4161/15384101.2014.947759.
5
Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.靶向 microRNA-214 治疗皮肤 T 细胞淋巴瘤的临床前研究
J Invest Dermatol. 2019 Sep;139(9):1966-1974.e3. doi: 10.1016/j.jid.2019.01.033. Epub 2019 Mar 12.
6
Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.miR-29b 水平降低与 BRD4 介导的皮肤 T 细胞淋巴瘤中癌基因的激活有关。
Blood. 2018 Feb 15;131(7):771-781. doi: 10.1182/blood-2017-09-805663. Epub 2017 Nov 27.
7
Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.抑癌 microRNA-124 的表观遗传沉默直接支持皮肤 T 细胞淋巴瘤中 STAT3 的激活。
Cells. 2020 Dec 15;9(12):2692. doi: 10.3390/cells9122692.
8
Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma.miR-26 的下调通过靶向白细胞介素-22 促进皮肤 T 细胞淋巴瘤的侵袭和转移。
Cancer Sci. 2022 Apr;113(4):1208-1219. doi: 10.1111/cas.15296. Epub 2022 Feb 20.
9
miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.miR-337 通过 STAT3 通路抑制皮肤 T 细胞淋巴瘤。
Cell Cycle. 2019 Jul;18(14):1635-1645. doi: 10.1080/15384101.2019.1629789. Epub 2019 Jun 18.
10
Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.Jak3、STAT3和STAT5抑制皮肤T细胞淋巴瘤中一种新型肿瘤抑制性微小RNA——miR-22的表达。
Oncotarget. 2015 Aug 21;6(24):20555-69. doi: 10.18632/oncotarget.4111.

引用本文的文献

1
A novel knockout mouse model to assess the impact of one-copy loss of Hnrnpk in CD4 + T cells in chronically inflamed skin as a prelude to CTCL.一种新型基因敲除小鼠模型,用于评估慢性炎症皮肤中CD4 + T细胞中Hnrnpk单拷贝缺失对蕈样肉芽肿前期的影响。
Sci Rep. 2025 Apr 24;15(1):14364. doi: 10.1038/s41598-025-98640-6.
2
Therapeutic Targeting of the Janus Kinase/Signal Transducer and Activator of Transcription Pathway in Cutaneous T-Cell Lymphoma.皮肤T细胞淋巴瘤中Janus激酶/信号转导及转录激活因子通路的治疗靶向作用
Cancers (Basel). 2025 Feb 7;17(4):568. doi: 10.3390/cancers17040568.
3
Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma.

本文引用的文献

1
The polymorphisms of IL-6/STAT3 signaling pathway may contribute to cutaneous T-cell lymphomas susceptibility.白细胞介素-6/信号转导与转录激活因子3信号通路的多态性可能与皮肤T细胞淋巴瘤易感性有关。
Arch Dermatol Res. 2021 Jan;313(1):25-31. doi: 10.1007/s00403-020-02062-5. Epub 2020 Apr 8.
2
EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.EBV 微小 RNA-BHRF1-2-5p 靶向免疫检查点配体 PD-L1 和 PD-L2 的 3'UTR。
Blood. 2019 Dec 19;134(25):2261-2270. doi: 10.1182/blood.2019000889.
3
Tumour-intrinsic resistance to immune checkpoint blockade.
度伐利尤单抗(抗程序性死亡配体1)联合来那度胺用于复发/难治性皮肤T细胞淋巴瘤的1期试验
Blood Adv. 2025 May 13;9(9):2247-2260. doi: 10.1182/bloodadvances.2024014655.
4
Is Kaposi sarcoma a novel comorbidity of cutaneous lymphoma? A systematic review of the literature.卡波西肉瘤是皮肤淋巴瘤的一种新型合并症吗?文献系统综述。
J Dtsch Dermatol Ges. 2025 Apr;23(4):467-477. doi: 10.1111/ddg.15625. Epub 2025 Jan 16.
5
The Tumor Microenvironment as a Therapeutic Target in Cutaneous T Cell Lymphoma.肿瘤微环境作为皮肤T细胞淋巴瘤的治疗靶点
Cancers (Basel). 2024 Oct 1;16(19):3368. doi: 10.3390/cancers16193368.
6
Non-coding RNAs in the spotlight of the pathogenesis, diagnosis, and therapy of cutaneous T cell lymphoma.非编码RNA在皮肤T细胞淋巴瘤发病机制、诊断及治疗中的研究热点
Cell Death Discov. 2024 Sep 10;10(1):400. doi: 10.1038/s41420-024-02165-2.
7
Hsa_circRNA_101036 aggravates hypoxic-induced endoplasmic reticulum stress via the miR-21-3p/TMTC1 axis in oral squamous cell carcinoma.人环状RNA Hsa_circRNA_101036通过miR-21-3p/TMTC1轴加重口腔鳞状细胞癌中的缺氧诱导内质网应激。
Heliyon. 2024 Jun 13;10(12):e32969. doi: 10.1016/j.heliyon.2024.e32969. eCollection 2024 Jun 30.
8
Role of microRNAs in Immune Regulation with Translational and Clinical Applications.miRNAs 在免疫调控中的作用及其转化和临床应用。
Int J Mol Sci. 2024 Feb 5;25(3):1942. doi: 10.3390/ijms25031942.
9
Unraveling the Mechanisms of PD-1 Regulation in Sézary Syndrome: Epigenetic Regulation as Potential Mechanism?解析蕈样肉芽肿中PD-1调控机制:表观遗传调控是潜在机制吗?
J Invest Dermatol. 2023 Dec;143(12):2338-2339. doi: 10.1016/j.jid.2023.06.197. Epub 2023 Aug 22.
10
Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma.抗 PD-L1 和来那度胺重编程 PD-1+M2 样肿瘤相关巨噬细胞治疗皮肤 T 细胞淋巴瘤。
JCI Insight. 2023 Jul 10;8(13):e163518. doi: 10.1172/jci.insight.163518.
肿瘤内在的免疫检查点阻断耐药性。
Nat Rev Immunol. 2020 Jan;20(1):25-39. doi: 10.1038/s41577-019-0218-4. Epub 2019 Sep 30.
4
Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment.癌症中的免疫调节 microRNAs:靶向免疫检查点和肿瘤微环境。
FEBS J. 2019 Sep;286(18):3540-3557. doi: 10.1111/febs.15000. Epub 2019 Jul 27.
5
Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sézary syndrome.在蕈样肉芽肿病中,LAG-3 与 BTLA、TIGIT 和 FCRL3 的表达呈分歧性。
Leuk Lymphoma. 2019 Aug;60(8):1899-1907. doi: 10.1080/10428194.2018.1564827. Epub 2019 Jan 14.
6
Role of miRNAs in immune responses and immunotherapy in cancer.miRNAs 在癌症免疫反应和免疫治疗中的作用。
Genes Chromosomes Cancer. 2019 Apr;58(4):244-253. doi: 10.1002/gcc.22725.
7
Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma.考博马林,一种 miR-155 的寡核苷酸抑制剂,协调调节多种存活途径,减少皮肤 T 细胞淋巴瘤中的细胞增殖和存活。
Br J Haematol. 2018 Nov;183(3):428-444. doi: 10.1111/bjh.15547. Epub 2018 Aug 20.
8
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.致癌激活 STAT3 通路驱动自然杀伤/T 细胞淋巴瘤中 PD-L1 的表达。
Blood. 2018 Sep 13;132(11):1146-1158. doi: 10.1182/blood-2018-01-829424. Epub 2018 Jul 27.
9
CellProfiler 3.0: Next-generation image processing for biology.CellProfiler 3.0:生物学的下一代图像处理。
PLoS Biol. 2018 Jul 3;16(7):e2005970. doi: 10.1371/journal.pbio.2005970. eCollection 2018 Jul.
10
Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.原发性皮肤 T 细胞淋巴瘤皮肤外植体中的初始 T 细胞表现出衰竭的免疫检查点特征。
Cancer Immunol Res. 2018 Aug;6(8):900-909. doi: 10.1158/2326-6066.CIR-17-0270. Epub 2018 Jun 12.